

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BRANCACCIO et al.

Appln. No. 10/538,736

Filed: August 11, 2005



Confirmation No. 7505

Atty. Ref.: 4636-25

Group Art Unit: 1632

Examiner: M.C. Gemeniano

**FOR: MELUSIN, A MUSCLE SPECIFIC PROTEIN, AS A DRUG TARGET FOR
PREVENTION AND TREATMENT OF HEART FAILURE**

* * * * *

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(c)

July 27, 2006

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Further to the Information Disclosure Statement (IDS) of June 14, 2005, attached is Form PTO-1449 listing the enclosed non-U.S. patent documents.

The Official Fee required under 37 CFR § 1.97(c) is filed herewith. But should that fee be missing or inadequate, please charge the deficiency to our Deposit Account No. 14-1140 under Order No. 4636-25.

This Information Disclosure Statement (IDS) is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to enable Applicants to comply fully. In particular, if any of the

listed documents are missing or incomplete, please contact the undersigned who will provide another copy.

As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this information and the listed references are prior art merely because they have been submitted for consideration. Furthermore, no representation is being made that a search has been conducted or that this statement encompasses all possible material information.

Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per M.P.E.P. § 609, are earnestly solicited. The Examiner is invited to contact the undersigned if any further information is needed.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:


Gary R. Tanigawa
Reg. No. 43,180

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION		APPLN. NO.	ATTY. DKT. NO.
		10/538,736	4636-25
		APPLICANT	
(Use several sheets if necessary)		BRANCACCIO et al.	
		FILING DATE	GROUP
		August 11, 2005	1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AR						
BR						
CR						

JUL 27 2006

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
DR						
ER						
FR						
GR						
HR						
IR						
JR						
KR						
LR						
MR						
NR						
OR						
PR						

OTHER DOCUMENTS (including Author, Title, Pertinent pages, Date, etc.)

QR	Cervenka et al. "Early onset salt-sensitive hypertension in bradykinin B ₂ receptor null mice" Hypertension 34:176-180 (1999)
RR	Eyestone "Production and breeding of transgenic cattle using in vitro embryo production technology" Theriogenol. 51:509-517 (1999)
SR	Hirsch et al. "Tissue-specific KO of ECM proteins" Meth. Mol. Biol. 139:147-178 (2000)
TR	Niemann et al. "Expression of human blood clotting factor VIII in the mammary gland transgenic sheep" Transgenic Res. 8:237-247 (1999)
UR	Niemann et al. "Progress in reproductive biotechnology in swine" Theriogenol. 56:1291-1304 (2001)
VR	Rockman et al. "Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy" Proc. Natl. Acad. Sci. USA 88:8277-8281 (1991)
WR	Strachan et al. "An overview of genetic manipulation of animals" Human Molecular Genetics, 2 nd Ed., Chapter 21, pp. 491-501 (1999)
ZR	van Berkel et al. "Large scale production of recombinant human lactoferrin in the milk of transgenic cows" Nat. Biotechnol. 20:484-487 (2002)
AAR	Vecchione et al. "Cardiovascular influences of α _{1b} -adrenergic receptor defect in mice" Circulation 105:1700-1707" (2002)
BBR	Wang et al. "Transgenic goats produced by DNA pronuclear microinjection of in vitro derived zygotes" Mol. Reprod. Dev. 63:437-443 (2002)
CCR	

*Examiner _____ Date Considered _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.